This podcast episode discusses Ozempic (semaglutide), a GLP-1 receptor agonist initially used for type 2 diabetes, now gaining popularity for weight loss. The episode details its mechanism of action, effectiveness (showing up to 15% weight loss in trials but with caveats regarding individual responses and potential for weight regain), safety (including common and rare side effects), ethical considerations (addressing societal pressures and the need for holistic care), and cost (highlighting affordability issues and the need for equitable access). The podcast aims to inform healthcare professionals and the public about the drug's benefits, limitations, and broader implications.

Hosted on Acast. See acast.com/privacy for more information.